Interim report January–June 2026: Strong lice...

Surgical Science delivers strong Q2 growth and swings to profitability.

What the company is saying

Surgical Science Sweden AB reports a 22 percent increase in net sales for Q2 2026, reaching SEK 254.5 million. The company highlights a gross margin improvement to 69 percent and a turnaround in operating profit from SEK -22.4 million to SEK 32.7 million. License revenue rose to SEK 84.8 million, now comprising 33 percent of net sales. Management, led by CEO Tom Englund and CFO Anna Ahlberg, frames the narrative around robust realised financials and operational progress. The announcement acknowledges the cancellation of a Memorandum of Understanding with Intuitive but asserts that the revenue loss for 2026 will be less than the previously indicated SEK 60–90 million. The tone is confident and data-driven, with emphasis on realised results and only one forward-looking assessment, which is conservatively stated.

What the data suggests

Net sales rose from SEK 209.2 million in Q2 2025 to SEK 254.5 million in Q2 2026, a 22 percent increase, with a 25 percent rise in local currencies. Gross margin improved from 65 percent to 69 percent, indicating better cost management or pricing power. Operating profit swung from a SEK -22.4 million loss to a SEK 32.7 million profit, and net profit improved from SEK -20.1 million to SEK 20.8 million, corresponding to earnings per share of SEK 0.41 versus SEK -0.39. Cash and cash equivalents increased to SEK 658.4 million as of June 30, 2026, up from SEK 610.2 million a year earlier. Cash flow from operating activities was SEK 15.3 million for the quarter, slightly down from SEK 16.2 million, but the first half figure of SEK 80.6 million is a substantial increase from SEK 11.3 million. The data is comprehensive, with all key metrics disclosed and no material gaps. The only unsupported claim is the forward-looking assessment of revenue loss from the Intuitive cancellation, which lacks a detailed breakdown.

Analysis

The announcement is highly factual and supported by detailed, realised financial metrics, including net sales, gross margin, operating profit, net profit, and cash flow. The only forward-looking statement concerns an assessed revenue loss for 2026, which is presented cautiously and does not inflate expectations. All other claims are realised and numerically substantiated, with clear year-over-year improvements in profitability and cash position. There is no evidence of narrative inflation or exaggerated language; the tone is proportionate to the results. No large capital outlay or long-dated, uncertain returns are discussed. The data fully supports the positive narrative, and the gap between narrative and evidence is negligible.

Risk flags

• ●The forward-looking assessment of revenue loss from the Intuitive cancellation is not supported by detailed calculations or contract disclosures, introducing uncertainty about the actual impact on 2026 results. Without a breakdown, investors cannot independently verify the magnitude or timing of the revenue shortfall.
• ●Despite strong realised results, the company’s future growth may depend on replacing lost business from Intuitive, and no new offsetting agreements or pipeline details are disclosed in this update. This leaves open the risk of a revenue gap in subsequent periods if replacement deals do not materialise.
• ●Cash flow from operating activities for Q2 2026 was SEK 15.3 million, slightly below the SEK 16.2 million in Q2 2025, suggesting that while profitability has improved, cash conversion in the quarter did not accelerate. If this trend persists, it could signal working capital or collection challenges.

Bottom line

Surgical Science Sweden AB’s Q2 2026 report shows a clear return to profitability and strong top-line growth, with all key financial metrics improving year-over-year. The company’s narrative is well-supported by detailed disclosures, and the only forward-looking claim—regarding revenue loss from the Intuitive cancellation—remains unquantified and thus cannot be independently validated. No new commercial wins or contracts are announced to offset this risk. The results are credible and actionable for investors focused on realised performance, but future updates should address how lost Intuitive revenue will be replaced. The most important takeaway is that the company has delivered a strong operational turnaround, but the sustainability of this momentum depends on securing new business to fill the Intuitive gap.

Announcement summary

(LSE/AIM:0AAU) Surgical Science Sweden AB reported net sales of SEK 254.5 million for the second quarter of 2026, an increase of 22 percent compared with the corresponding period in the preceding year. License revenue for the second quarter amounted to SEK 84.8 million and accounted for 33 percent of net sales. The gross margin for the second quarter was 69 percent. Operating profit for the second quarter amounted to SEK 32.7 million. Net profit for the second quarter amounted to SEK 20.8 million, corresponding to earnings per share of SEK 0.41. As at June 30, 2026, cash and cash equivalents amounted to SEK 658.4 million. Surgical Science Sweden AB has approximately 320 employees.

Disagree with this article?